Arlington Partners’s AbbVie ABBV Stock Holding History

Arlington Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-539	Closed	-$83.5K	–	62
2023 Q4	$83.5K	Buy	+539	New	+$78.6K	0.02%	112
2023 Q3	–	Sell	-4,006	Closed	-$540K	–	326
2023 Q2	$540K	Sell	4,006 -771	-16%	-$113K	0.08%	79
2023 Q1	$761K	Buy	4,777 +2,564	+116%	+$392K	0.11%	63
2022 Q4	$358K	Sell	2,213 -1,923	-46%	-$295K	0.06%	73
2022 Q3	$555K	Sell	4,136 -263	-6%	-$37.7K	0.22%	55
2022 Q2	$674K	Buy	4,399 +671	+18%	+$103K	0.22%	54
2022 Q1	$604K	Hold	3,728	–	–	0.17%	59
2021 Q4	$505K	Buy	3,728 +254	+7%	+$30K	0.14%	70
2021 Q3	$375K	Buy	+3,474	New	+$397K	0.11%	72
2020 Q3	–	Sell	-42	Closed	-$4K	–	138
2020 Q2	$4K	Sell	42 -37	-47%	-$3.26K	﹤0.01%	139
2020 Q1	$6K	Buy	+79	New	+$6.73K	﹤0.01%	174
2018 Q4	–	Sell	-1,002	Closed	-$95K	–	210
2018 Q3	$95K	Buy	+1,002	New	+$95K	0.07%	96

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Arlington Partners's ABBV Position: Q1 2024 in Review

Arlington Partners sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 539 shares — an estimated $83.5K sold.

Arlington Partners first reported a position in ABBV in Q3 2018 and held it in 12 quarters. The position peaked at $761K in Q1 2023. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

Arlington Partners reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
Arlington Partners sold 539 AbbVie shares in Q1 2024, an estimated $83.5K.
Arlington Partners first reported a position in AbbVie in Q3 2018 and held it in 12 quarters.
Arlington Partners's AbbVie position peaked at $761K in Q1 2023.
3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Arlington Partners's 13F filing for Q1 2024, filed 16 Apr 2024.